Article citationsMore>>
J. E. Cortes, D. Jones, S. O’Brien, E. Jabbour, F. Ravandi, C. Koller, et al., “Results of Dasatinib Therapy in Patients with Early Chronic-Phase Chronic Myeloid Leukemia,” Journal of Clinical Oncology, Vol. 28, No. 3, 2010, 398-404. doi;10.1200/JCO.2009.25.4920
has been cited by the following article:
-
TITLE:
Dasatinib-Induced Hepatic Dysfunction
AUTHORS:
Arumugam Manoharan
KEYWORDS:
Dasatinib; Hepatic Dysfunction; Reversibility
JOURNAL NAME:
International Journal of Clinical Medicine,
Vol.4 No.1,
January
18,
2013
ABSTRACT:
A 53-year-old man with chronic myeloid leukaemia developed significant hepatic dysfunction when treatment was changed from imatinib (because of drug-induced rash) to dasatinib. Liver function tests returned to normal 77 days after cessation of therapy and have remained normal despite recommencement of dasatinib. Although the pathogenesis for the significant hepatic dysfunction is unclear, this case illustrates the reversibility of this event with dose interruption and that dasatinib can be safely recommenced for ongoing treatment.
Related Articles:
-
Fabio Stagno, Paolo Vigneri, Massimo Poidomani, Stefania Stella, Alessandra Cupri, Michele Massimino, Livia Manzella, Francesco Di Raimondo
-
Bérénice Dégboé, Christiane Koudoukpo, Mouhaéminath Alimi, Ghislain Emmanuel Sopoh, Fabrice Akpadjan, Roch Christian Johnson, Nadège Agbéssi, Hugues Adégbidi, Félix Atadokpèdé
-
Jai Dev Chandel, Nand Lal Singh
-
Ullagaddi Rajeshwari, Iyer Shobha, Rao Raghunatha, Bondada Andallu
-
Marta Zapata-Tarrés, Rocío Cárdenas-Cardós, Liliana Velasco-Hidalgo, Martín Pérez-García, Alberto Olaya-Vargas, Daniela Cárdenas-Pedraza, Roberto Rivera-Luna